SCYNEXIS is a biotechnology company. Co. is developing its main product candidate, ibrexafungerp, as an intravenous/oral agent for multiple fungal indications in both the community and hospital settings. The U.S. Food and Drug Administration has approved BREXAFEMME (ibrexafungerp tablets) for treatment of patients with vulvovaginal candidiasis, also known as vaginal yeast infection, and for the reduction in the incidence of recurrent vulvovaginal candidiasis, respectively. Co. is also continuing on-going clinical studies of ibrexafungerp for multiple indications, including the treatment of life-threatening invasive fungal infections in hospitalized patients. The SCYX stock yearly return is shown above.
The yearly return on the SCYX stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2023 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the SCYX annual return calculation with any dividends reinvested as applicable (on ex-dates).
|